Abbott just announced a “medical device correction” for approximately three million glucose sensor monitors in the U.S., ...

The correction relates to around three million sensors used in Abbott’s FreeStyle Libre 3 and Libre 3 Plus CGMs in the US.

The correction is one of the largest in Abbott's recent continuous glucose monitor business, which dominates the global ...

Abbott has initiated a medical device correction for certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors ...

Abbot has issued a medical device correction for some of its glucose sensor products after identifying a manufacturing issue that can lead to falsely low glucose readings. The correction affects about ...

Abbott issued a medical device correction for some of its glucose sensors after internal testing found that some sensors may ...

According to Precedence Research, the global glucose biosensors market size will grow from USD 10.71 billion in 2025 to nearly USD 23.08 billion by 2034, with an expected CAGR of 8.91% from 2025 to ...

It's important to understand that the symptoms of hypoglycemia can vary significantly from person to person. Therefore, monitoring blood glucose levels regularly, especially for those at risk, is ...

Healthcare major Abbott has launched its next-generation continuous glucose monitoring (CGM) device, the FreeStyle Libre 2 Plus, in India, offering real-time glucose readings every minute and optional ...

Abbott announced the launch of the FreeStyle Libre 2 Plus sensor, Abbott’s latest addition to the FreeStyle Libre sensor portfolio. This device offers automatic glucose readings every minute straight ...

A reader is convinced it’s best to wait before getting a Switch 2 and lays out five reasons why he’s going to hold back until at least next year. Nintendo’s new console is going to be out in just a ...